Clinical trial
COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)
NCT00132899 · University of Western Ontario, Canada, Other · Completed
Key facts
| NCT number | NCT00132899 |
|---|---|
| Title | COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) |
| Official title | A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination With Methotrexate for the Long-term Treatment of Crohn's Disease (CD) |
| Lead sponsor | University of Western Ontario, Canada, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Methotrexate, Placebo |
| Enrollment | 128 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Aug 22, 2005 |
| Last update posted | Dec 11, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: